Literature DB >> 11166378

N- and C-domains of HIV-1 gp41: mutation, structure and functions.

X N Dong1, Y Xiao, M P Dierich, Y H Chen.   

Abstract

Recent studies demonstrated that the N- and C-domains of HIV-1 gp41 is involved in virus-mediated membrane fusion resulting in HIV-entry into the target cells. Up to now, viral mutation baffled many scientists to develop effective vaccines and drugs against HIV-1. To acquire more information of mutation of gp41 and to reveal the relationship of structure and function of the N- and C-domains, we compared and analyzed amino acid sequences of the gp41 ectodomain (aa 512-681) of 862 isolates from most HIV-1 clades (including A, B, C, D, E, F, G, H, I, J and O clades). A consensus sequence of the ectodomain with the highest frequency emerging on each position is constituted. The fusion domain and the N-domain belong to the most conserved regions in gp41, and most variable residues assemble partial to the C terminal of gp41. The hydrophobicity of each position is also calculated. The a and d positions in the N-domain for maintaining stabilization of the trimeric coiled coil interactions are highly conservative, and the e and g positions in the C-domain to retain the interaction show also highly conservative. The strange high conservation of the c residues may have an implication in the coiled coil structure. The highly conserved residues form the lining of the hydrophobic cavity and the deep cavity is an ideal target for small molecular inhibitors. On the C-terminal of the C-domain there is a highly conserved segment GIVQQQ. They are intimately involved in forming the three interfaces between neighboring helices. The function of the N- and C-domains, such as binding to the potential cellular receptor and inducing protective activities, are also discussed. These studies on the mutation, structure and functions of the N- and C-domains suggested that both domains become a new focus to develop effective vaccine and antiviral drugs in the new strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166378     DOI: 10.1016/s0165-2478(00)00302-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.

Authors:  M L Bellows; M S Taylor; P A Cole; L Shen; R F Siliciano; H K Fung; C A Floudas
Journal:  Biophys J       Date:  2010-11-17       Impact factor: 4.033

2.  GLUE that sticks to HIV: a helix-grafted GLUE protein that selectively binds the HIV gp41 N-terminal helical region.

Authors:  Susanne N Walker; Rachel L Tennyson; Alex M Chapman; Alan J Kennan; Brian R McNaughton
Journal:  Chembiochem       Date:  2014-12-04       Impact factor: 3.164

3.  Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Authors:  Béatrice Labrosse; Laurence Morand-Joubert; Armelle Goubard; Séverine Rochas; Jean-Louis Labernardière; Jerôme Pacanowski; Jean-Luc Meynard; Allan J Hance; François Clavel; Fabrizio Mammano
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

5.  Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Authors:  Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M Lange; Min Lu; Ben Berkhout
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human imunodeficiency virus type 1 gp41 with patient data.

Authors:  Nathalie Boutonnet; Wouter Janssens; Carlo Boutton; Jean-Luc Verschelde; Leo Heyndrickx; Els Beirnaert; Guido van der Groen; Ignace Lasters
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

Authors:  R C Zahn; F G Hermann; E-Y Kim; M D Rett; S M Wolinsky; R P Johnson; F Villinger; D von Laer; J E Schmitz
Journal:  Gene Ther       Date:  2008-05-01       Impact factor: 5.250

8.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

9.  Virtual interactomics of proteins from biochemical standpoint.

Authors:  Jaroslav Kubrycht; Karel Sigler; Pavel Souček
Journal:  Mol Biol Int       Date:  2012-08-08

10.  Virion stiffness regulates immature HIV-1 entry.

Authors:  Hong-Bo Pang; Liron Hevroni; Nitzan Kol; Debra M Eckert; Marianna Tsvitov; Michael S Kay; Itay Rousso
Journal:  Retrovirology       Date:  2013-01-10       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.